Cargando…
Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses
Until recently, immune responses in filovirus survivors remained poorly understood. Early studies revealed IgM and IgG responses to infection with various filoviruses, but recent outbreaks have greatly expanded our understanding of filovirus immune responses. Immune responses in survivors of Ebola v...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584125/ https://www.ncbi.nlm.nih.gov/pubmed/28724616 http://dx.doi.org/10.1084/jem.20170161 |
_version_ | 1783261411524214784 |
---|---|
author | Stonier, Spencer W. Herbert, Andrew S. Kuehne, Ana I. Sobarzo, Ariel Habibulin, Polina Dahan, Chen V. Abramovitch James, Rebekah M. Egesa, Moses Cose, Stephen Lutwama, Julius Julian Lobel, Leslie Dye, John M. |
author_facet | Stonier, Spencer W. Herbert, Andrew S. Kuehne, Ana I. Sobarzo, Ariel Habibulin, Polina Dahan, Chen V. Abramovitch James, Rebekah M. Egesa, Moses Cose, Stephen Lutwama, Julius Julian Lobel, Leslie Dye, John M. |
author_sort | Stonier, Spencer W. |
collection | PubMed |
description | Until recently, immune responses in filovirus survivors remained poorly understood. Early studies revealed IgM and IgG responses to infection with various filoviruses, but recent outbreaks have greatly expanded our understanding of filovirus immune responses. Immune responses in survivors of Ebola virus (EBOV) and Sudan virus (SUDV) infections have provided the most insight, with T cell responses as well as detailed antibody responses having been characterized. Immune responses to Marburg virus (MARV), however, remain almost entirely uncharacterized. We report that immune responses in MARV survivors share characteristics with EBOV and SUDV infections but have some distinct differences. MARV survivors developed multivariate CD4(+) T cell responses but limited CD8(+) T cell responses, more in keeping with SUDV survivors than EBOV survivors. In stark contrast to SUDV survivors, rare neutralizing antibody responses in MARV survivors diminished rapidly after the outbreak. These results warrant serious consideration for any vaccine or therapeutic that seeks to be broadly protective, as different filoviruses may require different immune responses to achieve immunity. |
format | Online Article Text |
id | pubmed-5584125 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-55841252018-03-04 Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses Stonier, Spencer W. Herbert, Andrew S. Kuehne, Ana I. Sobarzo, Ariel Habibulin, Polina Dahan, Chen V. Abramovitch James, Rebekah M. Egesa, Moses Cose, Stephen Lutwama, Julius Julian Lobel, Leslie Dye, John M. J Exp Med Research Articles Until recently, immune responses in filovirus survivors remained poorly understood. Early studies revealed IgM and IgG responses to infection with various filoviruses, but recent outbreaks have greatly expanded our understanding of filovirus immune responses. Immune responses in survivors of Ebola virus (EBOV) and Sudan virus (SUDV) infections have provided the most insight, with T cell responses as well as detailed antibody responses having been characterized. Immune responses to Marburg virus (MARV), however, remain almost entirely uncharacterized. We report that immune responses in MARV survivors share characteristics with EBOV and SUDV infections but have some distinct differences. MARV survivors developed multivariate CD4(+) T cell responses but limited CD8(+) T cell responses, more in keeping with SUDV survivors than EBOV survivors. In stark contrast to SUDV survivors, rare neutralizing antibody responses in MARV survivors diminished rapidly after the outbreak. These results warrant serious consideration for any vaccine or therapeutic that seeks to be broadly protective, as different filoviruses may require different immune responses to achieve immunity. The Rockefeller University Press 2017-09-04 /pmc/articles/PMC5584125/ /pubmed/28724616 http://dx.doi.org/10.1084/jem.20170161 Text en © 2017 Stonier et al. http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Research Articles Stonier, Spencer W. Herbert, Andrew S. Kuehne, Ana I. Sobarzo, Ariel Habibulin, Polina Dahan, Chen V. Abramovitch James, Rebekah M. Egesa, Moses Cose, Stephen Lutwama, Julius Julian Lobel, Leslie Dye, John M. Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses |
title | Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses |
title_full | Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses |
title_fullStr | Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses |
title_full_unstemmed | Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses |
title_short | Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses |
title_sort | marburg virus survivor immune responses are th1 skewed with limited neutralizing antibody responses |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584125/ https://www.ncbi.nlm.nih.gov/pubmed/28724616 http://dx.doi.org/10.1084/jem.20170161 |
work_keys_str_mv | AT stonierspencerw marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses AT herbertandrews marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses AT kuehneanai marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses AT sobarzoariel marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses AT habibulinpolina marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses AT dahanchenvabramovitch marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses AT jamesrebekahm marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses AT egesamoses marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses AT cosestephen marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses AT lutwamajuliusjulian marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses AT lobelleslie marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses AT dyejohnm marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses |